Sylvester Comprehensive Cancer Center, part of UHealth – the University of Miami Health System, announced today is it partnering with Syapse to launch a scalable precision medicine initiative that will benefit thousands of cancer patients in South Florida and improve survival rates. The partnership with Syapse will enable doctors at UMiami’s Sylvester Comprehensive Cancer Center to deliver personalized care that matches patients with targeted, cutting-edge cancer therapies, resulting in better health outcomes and lower costs.
With this partnership, Sylvester joins a growing number of leading health systems that are turning to precision medicine and choosing Syapse to do so, including Intermountain Healthcare, Providence St. Joseph’s Health, Stanford Healthcare, Henry Ford Health System, Catholic Health Initiatives, Dignity Health, and many more. Syapse powers the OPeN Network, the largest precision medicine data-consortium in the world, which Joe Biden announced last year as part of the Cancer Moonshot Initiative. The new partnership with Syapse allows Sylvester doctors to access that consortium.
The platform centralizes, organizes, and presents structured clinical and genomic data to providers at the point of care. The robust data infrastructure and provider-facing interface support complex clinical decisions, facilitate new provider workflows, and enable data-driven quality improvement efforts. Syapse enables data sharing across health systems, supporting the nation’s largest precision oncology data-sharing network. Health systems can access real-world treatment and outcomes data on clinically and molecularly similar patients, rapidly advancing the quality of care using real-world evidence.
“We are excited about this partnership with Syapse because it will help us ensure that our cancer patients receive the best precision care,” said Jonathan C. Trent, M.D., Ph.D., associate director of clinical research at Sylvester and professor of medicine at the University of Miami Miller School of Medicine. “Matching a cancer patient with a certain treatment based on the cancer’s molecular profile is among the most promising treatment options in this age of personalized medicine.”
“No other cancer center or hospital in South Florida offers the breadth of personalized treatment options as Sylvester,” said Trent. “At Sylvester, we understand that each patient is unique, that each cancer is unique, and, consequently, each cancer treatment has to be unique. This partnership with Syapse helps us achieve that goal.”